Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations

被引:42
|
作者
Skrabal, K [1 ]
Trouplin, V [1 ]
Labrosse, B [1 ]
Obry, V [1 ]
Damond, F [1 ]
Hance, AJ [1 ]
Clavel, F [1 ]
Mammano, F [1 ]
机构
[1] INSERM, U552, F-75018 Paris, France
关键词
HIV-1; antiretroviral therapy; tropism; plasma virus;
D O I
10.1097/00002030-200304110-00005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To study the impact of antiretroviral therapy on the tropism of plasma HIV-1 virus populations during treatment response and virological escape. Design: To investigate whether the selective pressure exerted by antiretroviral treatment influences the tropism of the plasma virus populations, we retrospectively determined the co-receptor usage of viruses present in plasma samples obtained before and at varying intervals after starting antiviral therapy. Methods: The co-receptor usage of plasma virus was determined using our recently published tropism recombinant test (V. Trouplin et al, J Virol, 2001; 75:251-259). This assay relies on virus production by homologous recombination between a plasmid encoding the entire HIV genome except for a deletion of the major tropism determinant, and a polymerase chain reaction (PCR) product spanning this region and the adjoining flanking sequences, obtained by reverse transcriptase (RT)-PCR amplification of viral RNA from the patient's plasma. Results: Twenty-four of the 32 patients analysed harboured exclusively R5 virus in plasma before the initiation of treatment, whereas eight had mixed R5/X4 virus populations. in four of these eight patients, all of whom initially responded to treatment, the persistence of R5 virus in plasma was observed, whereas the X4 component of the virus population became undetectable. The suppression of the X4 virus component was a transient phenomenon and variants able to use CXCR4 reemerged after a variable delay. Conclusions: The impact of therapy on virus populations differs according to virus tropism. Differences in target cell populations, tissue distribution and replication characteristics between R5 and X4 viruses could explain the preferential suppression of X4 virus. (C) 2003 Lippincott Williams Wilkins.
引用
收藏
页码:809 / 814
页数:6
相关论文
共 50 条
  • [31] EMERGENCE OF HIV-1 RESISTANCE MUTATIONS AT TREATMENT FAILURE AND CORRELATION WITH PLASMA ANTIRETROVIRAL DRUG LEVELS
    Fabbiani, M.
    Bracciale, L.
    Ragazzoni, E.
    De Simone, A.
    Santangelo, R.
    Cattani, P.
    Di Giambenedetto, S.
    Fadda, G.
    Navarra, P.
    Cauda, R.
    De Luca, A.
    INFECTION, 2009, 37 : 92 - 92
  • [32] Unconventional frontline antiretroviral treatment strategies in HIV-1 infection treatment
    Delaugerre, Constance
    Ghosn, Jade
    VIROLOGIE, 2012, 16 (06) : 371 - 380
  • [33] Phenotypic Correlates of HIV-1 Macrophage Tropism
    Arrildt, Kathryn T.
    LaBranche, Celia C.
    Joseph, Sarah B.
    Dukhovlinova, Elena N.
    Graham, William D.
    Ping, Li-Hua
    Schnell, Gretja
    Sturdevant, Christa B.
    Kincer, Laura P.
    Mallewa, Macpherson
    Heyderman, Robert S.
    Van Rie, Annelies
    Cohen, Myron S.
    Spudich, Serena
    Price, Richard W.
    Montefiori, David C.
    Swanstrom, Ronald
    JOURNAL OF VIROLOGY, 2015, 89 (22) : 11294 - 11311
  • [34] The effect of antiretroviral therapy without CCR5 antagonists on HIV-1 tropism in the MOTIVATE studies of maraviroc in treatment-experienced patients with R5 HIV-1
    Perno, C. F.
    Nelson, M.
    Waters, L.
    Clotet, B.
    Paredes, R.
    Heera, J.
    Mayer, H.
    Dang, N.
    Valdez, H.
    Van Der Ryst, E.
    ANTIVIRAL THERAPY, 2009, 14 (04) : A87 - A87
  • [35] Viral Determinants of HIV-1 Macrophage Tropism
    Duncan, Christopher J. A.
    Sattentau, Quentin J.
    VIRUSES-BASEL, 2011, 3 (11): : 2255 - 2279
  • [36] Emergence of HIV-1 Drug Resistance During Antiretroviral Treatment
    Libin Rong
    Zhilan Feng
    Alan S. Perelson
    Bulletin of Mathematical Biology, 2007, 69 : 2027 - 2060
  • [37] Prospective Antiretroviral Treatment of Asymptomatic, HIV-1 Infected Controllers
    Hatano, Hiroyu
    Yukl, Steven A.
    Ferre, April L.
    Graf, Erin H.
    Somsouk, Ma
    Sinclair, Elizabeth
    Abdel-Mohsen, Mohamed
    Liegler, Teri
    Harvill, Kara
    Hoh, Rebecca
    Palmer, Sarah
    Bacchetti, Peter
    Hunt, Peter W.
    Martin, Jeffrey N.
    McCune, Joseph M.
    Tracy, Russell P.
    Busch, Michael P.
    O'Doherty, Una
    Shacklett, Barbara L.
    Wong, Joseph K.
    Deeks, Steven G.
    PLOS PATHOGENS, 2013, 9 (10)
  • [38] Issues regarding antiretroviral treatment for patients with HIV-1 infection
    Macher, AM
    Goosby, EP
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 278 (15): : 1234 - 1235
  • [39] Emergence of HIV-1 drug resistance during antiretroviral treatment
    Rong, Libin
    Feng, Zhilan
    Perelson, Alan S.
    BULLETIN OF MATHEMATICAL BIOLOGY, 2007, 69 (06) : 2027 - 2060
  • [40] Concentrations of human immunodeficiency virus type 1 (HIV-1) RNA in cerebrospinal fluid after antiretroviral treatment initiated during primary HIV-1 infection
    Enting, RH
    Prins, JM
    Jurriaans, S
    Brinkman, K
    Portegies, P
    Lange, JMA
    CLINICAL INFECTIOUS DISEASES, 2001, 32 (07) : 1095 - 1099